Investigating inflammation in monocytes related to obesity
Inflammatory Status of Monocytes in Obesity: Association With Atherosclerosis Indicators and the Effectiveness of Weight Loss
This study is trying to see how weight loss affects inflammation in the blood cells of people with obesity and how that might relate to heart disease risk.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 50 Years to 80 Years |
| Sex | All |
| Sponsor | Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology Academic / other |
| Locations | 1 site (Moscow) |
| Trial ID | NCT05490862 on ClinicalTrials.gov |
What this trial studies
This study examines the pro-inflammatory activation of circulating monocytes and macrophages in individuals with obesity, focusing on their role in cardiovascular disease risk. Over a 12-week period, participants will undergo weight loss interventions while their inflammatory markers, mitochondrial genome mutations, and cardiovascular risk factors will be assessed. The research aims to understand the relationship between obesity, inflammation, and cardiovascular complications, particularly atherosclerosis. By analyzing these factors, the study seeks to provide insights into the mechanisms driving obesity-related cardiovascular issues.
Who should consider this trial
Good fit: Ideal candidates include individuals with a BMI of 30 kg/m2 or higher who are seeking weight loss interventions.
Not a fit: Patients with diabetes, cancer, uncontrolled hypertension, or severe chronic diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved strategies for managing obesity-related cardiovascular risks.
How similar studies have performed: Previous studies have shown promising results in understanding the role of inflammation in obesity and cardiovascular diseases, making this approach both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Obese Weight Loss and Control groups Inclusion Criteria: • BMI ≥30 kg/m2 Lean Control group Inclusion Criteria: • BMI \<25 kg/m2 Exclusion Criteria: * Diabetes Mellitus * Cancer * Uncontrolled Hypertension * Decompensated liver or kidney disease * III-IV classes of Chronic Heart Failure * Other chronic diseases (except CVDs) on permanent treatment.
Where this trial is running
Moscow
- Department of Cardiovascular Pathology and Diet — Moscow, Russian Federation (Recruiting)
Study contacts
- Principal investigator: Yurgita R Varaeva, MD, MRes — Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology
- Study coordinator: Yurgita R Varaeva, MD, MRes
- Email: varaeva@ion.ru
- Phone: +79253841894
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.